http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
원저(原著) : 간 질환자의 C형 간염항체 및 B형 간염항원 양성율
조창호 ( Chaog-ho Cho ),김창일 ( Chang-it Kim ),박경희 ( Kyung-hee Park ) 대한임상병리사협회 1994 임상수혈검사학회 발표자료집 Vol.1 No.1
In order to elucidate the prevalence of anti-HCV and HBsAg in liver disease patients, we examined anti-HCV and HBV markers in 359 samples from blood donors and 563 samples from liver disease patients using ELA method. The prevalence of anti-HCV in liver disease patients(12.1 %) was significantly higher than that(1.l %) of blood donors(P<0.05). Among blood donors the prevalence of anti-HCV in male(1.5 %) was not significantly higher than that(0.0%) in female. but in liver disease patients, male(14.1 %) was significantly higher than that(6.2%) in female. The positive rate of anti-HCV was significantly increased with age in liver disease patients(P<0.05), but in blood donors was not significantly. Anti-HCV was detected in 48.9 %(23/47) of hepatoma, 9.3 %(17/183) of liver cirrhosis, 8.4 %(28/333) of other chronic hepatitis. Relative risk for HBsAg was 6.98(95 % CI:4.11-11.86) in hepatoma(P<0.05). 3.60(95 % CI:2.86-4.53) in liver cirrhosis, 2.56(95 % CI: 2.10-2.88) in other chronic hepatitis. For anti-HCV, the relative risk in hepatoma was 13.45(95 % CI:8.91-20.32), in liver cirrhosis was 2.54(95 % CI:1.72-3.76), in other chronic hepatitis was 1.89(95 % CI: 1.44-2.49). These findings provide strong evidence that HCV infection is significantly correlated with hepatoma, and may even playa more important role than the hepatitis B virus.